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Abstract
Antigen-specific immunotherapy using DNA vaccines has emerged as an attractive approach for the control of
tumors. Another novel cancer therapy involves the employment of the vascular disrupting agent, 5,6-
dimethylxanthenone-4-acetic acid (DMXAA). In the current study, we aimed to test the combination of DMXAA
treatment with human papillomavirus type 16 (HPV-16) E7 DNA vaccination to enhance the antitumor effects and
E7-specific CD8+ T cell immune responses in treated mice. We determined that treatment with DMXAA generates
significant therapeutic effects against TC-1 tumors but does not enhance the antigen-specific immune responses in
tumor bearing mice. We then found that combination of DMXAA treatment with E7 DNA vaccination generates
potent antitumor effects and E7-specific CD8+ T cell immune responses in the splenocytes of tumor bearing mice.
Furthermore, the DMXAA-mediated enhancement or suppression of E7-specific CD8+ T cell immune responses
generated by CRT/E7 DNA vaccination was found to be dependent on the time of administration of DMXAA and
was also applicable to other antigen-specific vaccines. In addition, we determined that inducible nitric oxide
synthase (iNOS) plays a role in the immune suppression caused by DMXAA administration before DNA vaccination.
Our study has significant implications for future clinical translation.
Introduction
Advanced stage cancers are difficult to control using
conventional therapies such as chemotherapy, surgery
and radiation. Therefore, new innovative therapies are
urgently required in order to combat the high mortality
and morbidity associated with cancers. Antigen-specific
immunotherapy has emerged as an attractive approach
for the treatment of cancers since it has the ability to
specifically eradicate systemic tumors and control
metastases without damaging normal cells. DNA vacci-
nation has become a potentially promising approach for
antigen-specific immunotherapy due to its safety, stabi-
lity and ease of preparation (for review, see [1,2]). We
have previously developed several innovative strategies
to enhance DNA vaccine potency by directly targeting
the DNA into the dendritic cells (DCs) in vivo via gene
g u na sw e l la sb ym o d i f y i n gt h ep r o p e r t i e so fa n t i g e n -
expressing DCs (for review see [3,4]).
One of the strategies to enhance DNA vaccine
potency uses intracellular targeting strategies to enhance
MHC class I/II antigen presentation and processing in
DCs. Previously, we have studied the linkage of calreti-
culin (CRT), a Ca
2+-binding protein located in the endo-
plasmic reticulum (ER) (for review, see [5]) to several
antigens, including human papillomavirus type-16
(HPV-16) E7 [6,7], E6 [8], and nucleocapsid protein of
severe acute respiratory syndrome (SARS) coronavirus
[9]. Intradermal administration of CRT linked to any of
these target antigens led to a significant increase in the
antigen-specific CD8+ T cell immune responses and
impressive antitumor effects. Thus, CRT has been
shown to be highly potent in enhancing the antigen-spe-
cific immune responses and antitumor effects generated
by DNA vaccination in several preclinical models.
Another novel cancer therapy involves the employment
of the vascular disrupting agent, 5,6-dimethylxanthenone-
4-acetic acid (DMXAA). Vascular disrupting agents are a
new class of potential anticancer drugs that selectively
destroy the established tumor vasculature and shutdown
blood supply to solid tumors, causing extensive tumor cell
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any medium, provided the original work is properly cited.necrosis (For reviews see [10,11]). DMXAA is a synthetic
flavonoid that induces the production of local cytokines
including TNFa. DMXAA has been shown to induce anti-
tumor effects in animal models, especially in combination
with established anticancer agents. It has demonstrated a
good safety profile and has been shown to be promising in
phase I clinical trials [12].
In the current study, we aimed to test the combina-
tion of DMXAA treatment with E7 DNA vaccination to
enhance the antitumor effects and E7-specific CD8+ T
cell immune responses in treated mice. We also aimed
at exploring the appropriate regimen and the mechan-
ism of action of this drug. The clinical implications of
the current study are discussed.
Materials and methods
Mice
C57BL/6 mice (5- to 8-week-old) were purchased from
the National Cancer Institute (Frederick, MD). 5-8 week-
old inducible nitric oxide synthase deficient (iNOS
-/-)
and wild-type control C57BL/6 mice were purchased
from Jackson Laboratories (Bar Harbor, ME). 5-8 week
old TNFa-/- and wild-type control C57BL/6 mice were
purchased from Taconic (Hudson, NY). All animals were
maintained under specific-pathogen free conditions, and
all procedures were performed according to approved
protocols and in accordance with recommendations for
the proper use and care of laboratory animals.
Peptides, antibodies and regents
The H-2K
b restricted HPV-16 E6 peptide, YDFAFRDL (E6
aa50-57), and the H-2D
b restricted HPV-16 E7 peptide,
RAHYNIVTF (E7 aa49-57) were synthesized by Macromo-
lecular Resources (Denver, CO) at a purity of ≥70%. FITC-
conjugated rat anti-mouse CD4, CD8, IFN-g and
PE-conjugated anti-mouse CD8 antibodies were purchased
from BD Pharmingen (BD Pharmingen, San Diego, CA).
5,6-dimethylxanthenone-4-acetic acid (DMXAA) was pur-
chased from Sigma (St. Louis, MO). DMXAA was dissolved
in 5% sodium bicarbonate, and injected intraperitoneally
(i.p.) at a dose of 20 mg/kg of body weight.
Cells
HPV-16 E6 and E7-expressing TC-1 tumor cells were
generated as previously described [13] and was grown in
RPMI 1640 medium containing 10% fetal bovine serum,
2 mM glutamine, 1 mM sodium pyruvate, 100 IU/ml
penicillin, 100 μg/ml streptomycin, 100 μMn o n - e s s e n -
tial amino acids and 0.4 mg/ml of G418.
Vaccines
The generation of HPV-16 E7-expressing plasmid
(pcDNA3-CRT/E7), E6-expressing plasmid (pcDNA3-
C R T / E 6 )[ 8 ] ,P A D R E - e x p r e s s i n gp l a s m i d( p c D N A 3 -
IiPADRE) [14], and vaccinia virus encoding HPV-16 E7
(SigE7LAMP1) [15], has been described previously.
Mouse tumor challenge model
C57BL/6 mice (five per group) were injected with 1 ×
10
5 TC-1 tumor cells subcutaneously at the flank site in
100 μL PBS. Tumors were measured twice a week.
Tumor volume was estimated using the formula 3.14 ×
[largest diameter × (perpendicular diameter)
2]/6.
Vaccination
Preparation of DNA-coated gold particles and gene gun
particle-mediated DNA vaccination was performed
using a helium-driven gene gun (BioRad Laboratories
Inc., Hercules, CA) according to a protocol described
previously. Gold particles coated with pcDNA3 encoding
HPV-16 E6 or HPV-16 E7 or PADRE were delivered to
the shaved abdominal region of mice using a helium-
driven gene gun with a discharge pressure of 400 psi.
Mice were immunized with 2 μgo ft h ev a r i o u sD N A
vaccines and received boosts with the same regimen as
indicated in the figure legends. For vaccinia encoding
SigE7LAMP1 vaccination, 1 × 10
7 pfu viruses were
injected intraperitoneally in 100 μl volume. Splenocytes
were harvested 1 week after the last vaccination.
Intracellular cytokine staining and flow cytometry analysis
Before intracellular cytokine staining, pooled splenocytes
from each vaccination group were incubated for 20
hours with 1 μg/ml of the HPV-16 E6 aa50-57 peptide,
or HPV-16 E7aa49-57 peptide, or PADRE peptide at the
presence of GolgiPlug (BD Pharmingen, San Diego, CA).
The stimulated splenocytes were then washed once with
FACScan buffer and stained with PE-conjugated mono-
clonal rat antimouse CD8a (clone 53.6.7). Cells were
subjected to intracellular cytokine staining using the
Cytofix/Cytoperm kit according to the manufacturer’s
instruction (BD Pharmingen, San Diego, CA). Intracellu-
lar IFN-g was stained with FITC-conjugated rat anti-
mouse IFN-g. Flow cytometry analysis was performed
using FACSCalibur with CELLQuest software (BD bios-
ciences, Mountain View, CA).
Detection of T cell apoptosis
C57BL/6 mice were treated with DMXAA at 20 mg/kg
via i.p. injection. 48 hours later, splenocytes were har-
vested and apoptosis of T cells were analyzed by stain-
ing splenocytes with annexin V staining kit from BD
Pharmingen according to the protocol provided by the
manufacturer.
Bio-Plex cytokine assay
5~8 week-old C57BL/6 mice were vaccinated with 2 μg
of pcDNA3-CRT/E7 DNA via gene gun delivery. 3 days
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20 mg/kg of DMXAA or buffer via i.p. injection. Mouse
serum was collected 5 hours later and stored at -80°C
until assay. Mouse cytokines were analyzed using Bio-
Plex Pro Mouse Cytokine 23-plex Assay from Bio-Rad
according to manufacturer’s protocol. Each sample was
assayed in duplicate.
Statistical analysis
Data expressed as means ± standard deviations (SD) are
representative of at least two different experiments.
Comparisons between individual data points were made
by 2-tailed Student’s t test. A p value of less than 0.05
was considered significant.
Results
Treatment with DMXAA generates significant therapeutic
effects against TC-1 tumors but does not enhance the
antigen-specific immune responses in tumor bearing
mice
To determine the antitumor effects of treatment with
DMXAA, we first challenged groups of C57BL/6 mice
(5 per group) with TC-1 tumor cells and treated them
with a single dose of DMXAA which was administered on
day 13 after tumor challenge via i.p. injection and moni-
tored the tumor size over time. As shown in Figure 1A,
tumor bearing mice treated with DMXAA showed signifi-
cantly lower tumor volumes over time compared to tumor
bearing mice without DMXAA treatment (* p < 0.05). We
also characterized the E7-specific CD8
+ T cell immune
responses in these mice. One week after DMXAA treat-
ment, splenocytes from tumor-bearing mice were har-
vested and characterized for E7-specific CD8
+ T cells
using intracellular IFN-g staining followed by flow cytome-
try analysis. However, as shown in Figure 1B, we found
that mice treated with DMXAA were not capable of signif-
icantly enhancing the E7-specific CD8+ T cell immune
responses compared to mice without DMXAA treatment.
Taken together, our data indicate that treatment with
DMXAA generates significant therapeutic effects against
TC-1 tumors but does not enhance the antigen-specific
immune responses in tumor bearing mice.
Combination of DMXAA treatment with E7 DNA
vaccination generates potent antitumor effects and E7-
specific CD8+ T cell immune responses in the splenocytes
of tumor-bearing mice
In order to determine the therapeutic antitumor effects
and E7-specific CD8+ T cell immune response in TC-1
tumor-bearing mice treated with DMXAA combined
with CRT/E7 DNA vaccination, we first challenged
groups of C57BL/6 mice (5 per group) with TC-1 tumor
cells and then treated them with CRT/E7 DNA vaccine
with or without DMXAA as illustrated in Figure 2A.
Seven days after the last vaccination, we harvested sple-
nocytes from vaccinated mice and characterized them for
the presence of E7-specific CD8
+ T cells using intracellu-
lar cytokine staining for IFN-g followed by flow
Figure 1 Characterization of antitumor effects and E7-specific CD8+ T cell immune responses in TC-1 tumor-bearing mice treated with
DMXAA. 5-8 weeks old C57BL/6 mice (5 per group) were challenged with 1 × 10
5 TC-1 cells subcutaneously. Mice were treated with a single
dose of DMXAA given at day 13 after tumor challenge via i.p. injection. Tumor volume was monitored with calipers twice a week. One week
after DMXAA treatment, splenocytes from tumor-bearing mice were harvested and characterized for E7-specific CD8
+ T cells using intracellular
IFN-g staining followed by flow cytometry analysis. A) Line graph depicting the tumor volume in TC-1 tumor bearing mice treated with or
without DMXAA (mean+ s.e.) B) Representative data of intracellular cytokine staining followed by flow cytometry analysis showing the number
of E7-specific IFNg+ CD8+ T cells in after DMXAA treatment. The data shown here are from one representative experiment of two performed.
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ing mice that were treated with CRT/E7 DNA vaccine in
combination with DMXAA generated the best therapeu-
tic antitumor effects compared to mice treated with any
other regimens (* p < 0.05). Furthermore, mice treated
with DNA vaccine in combination with DMXAA also
generated the highest number of E7-specific CD8
+ T
cells compared to mice treated with any of the other regi-
mens. Thus, our results suggest that treatment of tumor-
bearing mice with DMXAA enhances the systemic E7-
specific CD8+ T cell immune responses and antitumor
effects generated by CRT/E7 DNA vaccination.
The DMXAA-mediated enhancement of E7-specific CD8+
T cell immune responses generated by CRT/E7 DNA
vaccination is dependent on the time of administration of
DMXAA
In order to determine the optimal regimen for enhan-
cing the antigen-specific CD8+ T cell immune responses
g e n e r a t e db yC R T / E 7D N Av a c c i n eu s i n gD M X A A ,
C57BL/6 mice (5 per group) were vaccinated with CRT/
E7 DNA vaccine three times at 3 day intervals via gene
gun delivery and treated with DMXAA at 3 days before
the first vaccination (-3), simultaneously (0) or 3 days
after the first vaccination (+3) as indicated in Figure 3A.
Vaccinated mice without DMXAA treatment were used
as controls. Seven days after the last vaccination, spleno-
cytes were harvested from vaccinated mice and charac-
terized for the presence of E7-specific CD8
+ Tc e l l s
using intracellular cytokine staining for IFN-g followed
by flow cytometry analysis. As shown in Figure 3B, vac-
cinated mice treated with DMXAA 3 days after vaccina-
tion generated the best E7-specific CD8+ T cell immune
responses compared to any of the other regimens.
Furthermore, we observed that vaccinated mice treated
with DMXAA at the time of vaccination or 3 days
before the first vaccination generated suppressed E7-
specific CD8+ T cell immune responses compared to
vaccinated mice without DMXAA treatment. Thus, our
data indicate that administration of DMXAA 3 days
Figure 2 Characterization of antitumor effects and E7-specific CD8+ T cell immune responses in tumor-bearing mice treated with HPV-
16 E7 DNA vaccine in combination with DMXAA. (A) Schematic diagram of the immunization regimen of the CRT/E7 DNA vaccine and/or
DMXAA. 5-8 weeks old C57BL/6 mice (5 per group) were challenged with 1 × 10
5 TC-1 tumor cells subcutaneously, and were vaccinated with
pcDNA3-CRT/E7 DNA vaccine or control vectors, and either treated with DMXAA or left untreated as indicated. Tumor volume was monitored with
calipers twice a week. One week after last vaccination, splenocytes from tumor-bearing mice were harvested and characterized for E7-specific CD8
+
T cells using intracellular IFN-g staining followed by flow cytometry analysis. A) Line graph depicting the tumor volume in TC-1 tumor bearing mice
treated with the various regimens (mean+ s.e.) B) Bar graph depicting the number of E7-specific IFNg+ CD8+ T cells per 3 × 10
5 splenocytes ± SEM
following DNA vaccination +/- DMXAA treatment. The data shown here are from one representative experiment of two performed.
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icantly enhanced E7-specific CD8+ T cell immune
responses in tumor-bearing mice.
In order to determine if the observed phenomenon is
also applicable to tumor-bearing mice, C57BL/6 mice (5
per group) were challenged with TC-1 tumor cells subcu-
taneously, vaccinated with pcDNA3-CRT/E7 DNA vaccine
via gene gun delivery, and treated with DMXAA either
before the first vaccination (d-3) or after the first vaccina-
tion (d+3) as indicated in Figure 4A. One week after last
vaccination, splenocytes from tumor-bearing mice were
harvested and characterized for E7-specific CD8
+ T cells
using intracellular IFN-g staining followed by flow cytome-
try analysis. As shown in Figure 4B, tumor-bearing mice
treated with DMXAA 3 days after the first vaccination (d
+3) generated significantly higher E7-specific CD8+ T cell
immune responses compared to tumor-bearing mice trea-
ted with DMXAA before vaccination (d-3) (p < 0.05). We
also observed that vaccinated tumor-bearing mice treated
with DMXAA at the time of vaccination or 3 days before
vaccination generated suppressed E7-specific CD8+ T cell
immune responses compared to vaccinated mice without
DMXAA treatment.
Furthermore, tumor-bearing mice treated with
DMXAA 3 days after the first vaccination (d+3) gener-
ated a significantly increased number of activated dendri-
tic cells compared to the control. In addition, treatment
with DMXAA also led to increased expression of co-sti-
mulatory markers for DC activation compared to the
control (see Additional File 1; Figure S1). The increased
number and function of DCs contribute to the enhanced
processing and presentation of E7 antigen to the genera-
tion of E7-specific CD8+ T cells in treated mice. Taken
together, our data indicate that the timing of administra-
tion of DMXAA significantly influences the E7-specific
CD8+ T cell immune responses in treated mice.
The DMXAA-mediated enhancement of antigen-specific T
cell-mediated immune responses generated by
vaccination is also applicable to other antigen-specific
vaccines
In order to determine if the observed enhancement of
HPV DNA vaccine-induced antigen-specific immune
responses by DMXAA is also applicable to other antigen-
Figure 3 Characterization of the E7-specific CD8+ T cell
immune responses in naïve mice treated with HPV-16 E7 DNA
vaccine in combination with DMXAA administered at different
time points. (A) Schematic diagram of the immunization regimen
of the CRT/E7 DNA vaccine and/or DMXAA administered at different
time points, either 3 days before the first vaccination (d-3),
simultaneously (d0) or 3 days after the first vaccination (d+3). 5-8
weeks old C57BL/6 mice were vaccinated with pcDNA3-CRT/E7 DNA
vaccine via gene gun delivery and treated with DMXAA as indicated
in Figure 3A. One week after last vaccination, splenocytes from
mice were harvested and characterized for E7-specific CD8
+ T cells
using intracellular IFN-g staining followed by flow cytometry
analysis. (B) Bar graph depicting the number of E7-specific IFNg+
CD8+ T cells per 3 × 10
5 splenocytes ± SEM following DNA
vaccination +/- DMXAA treatment. The data shown here are from
one representative experiment of two performed.
Figure 4 Characterization of the E7-specific CD8+ T cell
immune responses in tumor-bearing mice treated with HPV-16
E7 DNA vaccine in combination with DMXAA administered at
different time points. (A) Schematic diagram of the immunization
regimen of the CRT/E7 DNA vaccine and/or DMXAA administered at
different time points, either 3 days before the first vaccination (d-3)
or 3 days after the first vaccination (d+3). 5-8 weeks old C57BL/6
mice were challenged with 1 × 10
5 TC-1 tumor cells
subcutaneously, vaccinated with pcDNA3-CRT/E7 DNA vaccine via
gene gun delivery and treated with DMXAA as indicated in Figure
4A. One week after last vaccination, splenocytes from tumor-
bearing mice were harvested and characterized for E7-specific CD8
+
T cells using intracellular IFN-g staining followed by flow cytometry
analysis. (B) Bar graph depicting the number of E7-specific IFNg+
CD8+ T cells per 3 × 10
5 splenocytes ± SEM following DNA
vaccination +/- DMXAA treatment. The data shown here are from
one representative experiment of two performed.
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nated with CRT/E6 DNA or Sig/E7/L1 vaccinia virus or
PADRE DNA vaccine via gene gun delivery and treated
with DMXAA at 3 days before vaccination (-3), simulta-
neously (0) or 3 days after vaccination (+3) as indicated in
Figure 3A. One week after last vaccination, splenocytes
from mice were harvested and characterized for antigen-
specific T cell immune responses using intracellular IFN-g
staining followed by flow cytometry analysis. As shown in
Figure 5, mice vaccinated with the 3 different vaccines
(CRT/E6 DNA or Sig/E7/L1 vaccinia virus or PADRE
DNA) and treated with DMXAA 3 days after the first vac-
cination all generated the best antigen-specific T cell
immune responses ((A) HPV-16 E6-specific CD8
+ Tc e l l
responses, (B) HPV-16 E7-specific CD8
+ T cell responses,
and (C) PADRE-specific CD4
+ T cell immune responses)
compared to any of the other regimens. Thus, our data
indicate that administration of DMXAA three days after
the first vaccination is capable of enhancing antigen-speci-
fic immune responses in different vaccination systems.
In order to determine if additional doses of DMXAA
following the first vaccination would further enhance the
immune responses generated in vaccinated mice, C57BL/
6 mice (5 per group) were vaccinated with pcDNA3-
CRT/E7 DNA vaccine via gene gun delivery and treated
with either one dose or two doses of DMXAA as indi-
cated in Additional File 2; Figure S2A. One week after
last vaccination, splenocytes from mice were harvested
and characterized for E7-specific CD8
+ Tc e l l su s i n g
intracellular IFN-g staining followed by flow cytometry
analysis. As shown in Additional File 2; Figure S2B and
C, vaccinated mice treated with two doses of DMXAA
after vaccination generated significantly better E7-specific
CD8+ T cell immune responses compared to vaccinated
mice treated with one dose of DMXAA. Thus, our data
indicate that administration of two doses of DMXAA
after the first CRT/E7 DNA vaccination generates signifi-
cantly better E7-specific CD8+ T cell immune responses
in vaccinated mice compared to administration of one
dose of DMXAA.
Co-administration of DMXAA with CRT/E7 DNA vaccine
generates long term E7-specific memory CD8+ T cell
immune responses in vaccinated mice
In order to determine the long-term memory T cell
immune responses generated by CRT/E7 DNA vaccina-
tion with or without treatment with DMXAA, C57BL/6
mice (5 per group) were vaccinated with CRT/E7 DNA
vaccine three times with 3 day intervals via gene gun
delivery and treated with DMXAA at 3 days after vacci-
nation as indicated in Figure 6A. Sixty days after the last
treatment, we harvested splenocytes from vaccinated
mice and characterized them for the presence of E7-spe-
cific CD8
+ T cells using intracellular cytokine staining
for IFN-g followed by flow cytometry analysis. As shown
in Figure 6B, vaccinated mice treated with DMXAA 3
Figure 5 Characterization of the antigen-specific CD8+ T cell immune responses in mice treated with various vaccines in combination
with DMXAA administered at different time points. 5-8 weeks old C57BL/6 mice were vaccinated with CRT/E6 DNA via gene gun, Sig/E7/L1
vaccinia virus intraperitoneally or PADRE DNA vaccine via gene gun delivery and treated with DMXAA at 3 days before vaccination (-3),
simultaneously (0) or 3 days after vaccination (+3) as indicated in Figure 3A. One week after last vaccination, splenocytes from mice were
harvested and characterized for (A) HPV-16 E6aa50-57-specific CD8
+ T cell responses, (B) HPV-16 E7aa49-57-specific CD8
+ T cell responses, or (C)
PADRE-specific CD4
+ T cell responses using intracellular IFN-g staining followed by flow cytometry analysis. A&B . Bar graph depicting the
number of antigen-specific IFNg+ CD8+ T cells per 3 × 10
5 splenocytes ± SEM following vaccination +/- DMXAA treatment. C. Bar graph
depicting the number of antigen-specific IFNg+ CD4+ T cells per 3 × 10
5 splenocytes ± SEM following vaccination +/- DMXAA treatment. The
data shown here are from one representative experiment of two performed.
Peng et al. Journal of Biomedical Science 2011, 18:21
http://www.jbiomedsci.com/content/18/1/21
Page 6 of 11days after the first vaccination generated significantly
better E7-specific CD8+ memory T cell immune
responses compared to vaccination without DMXAA
treatment. Thus, our data indicate that administration
of DMXAA 3 days after the first CRT/E7 DNA vaccina-
tion enhances the E7-specific CD8+ memory T cell
immune responses in vaccinated mice.
Co-administration of DMXAA with DNA vaccine leads to
elevated levels of inflammatory cytokines in the serum of
treated mice
In order to determine if co-administration of DMXAA
with DNA vaccination will influence the cytokine level
in the serum of mice with observed immune enhance-
ment, we characterized the serum cytokine concentra-
tion from vaccinated mice treated with DMXAA 3 days
after the first vaccination (see Figure 6A) using
multiplex analysis. As shown in Figure 7, the cytokines
I L - 6 ,G - C S F ,K C ,M I P - 1 b,M C P - 1a n dR A N T E Sw e r e
found to be elevated in vaccinated mice treated with
DMXAA compared to vaccinated mice without
DMXAA treatment. These cytokines may potentially
play a role in the enhancement of antigen-specific T cell
immune responses caused by co-administration of
DMXAA with the DNA vaccine.
iNOS plays a role in the immune suppression caused by
DMXAA administration at the time of the first DNA
vaccination
In order to determine the mechanism by which
DMXAA leads to suppressed antigen-specific CD8+ T
cell immune responses when administered before or at
the time of the first DNA vaccination, we characterized
the apoptotic cell death of CD4+ and CD8+ T cells in
Figure 6 Characterization of the E7-specific memory CD8+ T cell immune responses in mice treated with HPV-16 E7 DNA vaccine in
combination with DMXAA. (A) Schematic diagram of the immunization regimen of the CRT/E7 DNA vaccine and/or DMXAA. 5-8 weeks old
C57BL/6 mice were vaccinated with pcDNA3-CRT/E7 DNA vaccine via gene gun delivery at day 0, 3 and 6 and DMXAA (20 mg/kg) was
administered on day 3 as depicted in Figure 6A. Sixty days after the first vaccination, splenocytes were harvested and characterized for E7-
specific CD8
+ T cells using intracellular IFN-g staining followed by flow cytometry analysis. (B) Representative data of intracellular cytokine
staining followed by flow cytometry analysis showing the number of E7-specific IFNg+ CD8+ T cells in after DNA vaccination +/- DMXAA
treatment. (C) Bar graph depicting the number of E7-specific IFNg+ CD8+ T cells per 3 × 10
5 splenocytes ± SEM following DNA vaccination +/-
DMXAA treatment. The data shown here are from one representative experiment of two performed.
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DMXAA. C57BL/6 mice (5 per group) were treated
with DMXAA at 20 mg/kg via i.p. injection. 48 hours
later, splenocytes were harvested and apoptosis of CD4+
and CD8+ T cells were analyzed by annexin V staining.
There was no significant difference in the levels of apop-
totic cell death in the CD4+ or CD8+ T cells among
splenocytes from mice treated with DMXAA compared
to those from the control mice (see Additional File 3;
Figure S3). Thus, our data suggest that the mechanism
by which DMXAA leads to suppressed antigen-specific
immune responses is not through T cell apoptosis.
It has been shown that mice treated with DMXAA
have been shown to induce iNOS production as well
as TNFa in tumors [16]. Furthermore, iNOS and
TNFa has been implicated in playing an important
role in antitumor immunity (for reviews, see [17-19].
Thus, in order to further explore the mechanism of
action of DMXAA related to iNOS and TNFa,w e
have used iNOS-/- mice or TNFa-/- mice as well as
C57BL/6 WT mice (5 per group) for our study. These
mice were vaccinated with CRT/E7 DNA vaccine via
gene gun delivery and treated with DMXAA either at
the time of first vaccination on D0 or 3 days after the
first vaccination on D3 as indicated in Figure 8A and
8D. One week after last vaccination, splenocytes from
vaccinated mice were harvested and characterized for
E7-specific CD8
+ T cells using intracellular IFN-g
staining followed by flow cytometry analysis. As shown
in Figure 8B, while DMXAA led to the suppression of
E7-specific CD8+ T cell immune responses in CRT/E7
vaccinated WT mice when administered on D0,
DMXAA did not suppress the E7-specific CD8+ T cell
immune responses in CRT/E7 vaccinated iNOS-/-
mice. This indicates that iNOS is a major factor in the
immunosuppression mediated by DMXAA when admi-
nistered at the time of the first DNA vaccination. On
the other hand, vaccinated TNFa-/- mice treated with
DMXAA administered on D0 suppressed the E7-speci-
fic CD8+ T cell immune responses similar to wild-type
mice (see Figure 8C). We also found that vaccinated
iNOS-/- mice or TNFa-/- mice treated with DMXAA
on D3 led to enhancement E7-specific CD8+ T cell
immune responses similar to wild-type mice (Figure 8E
Figure 7 Multiplex analysis to determine the serum cytokine concentration from CRT/E7 DNA vaccinated mice either treated with
DMXAA. 5-8 week-old C57BL/6 mice were vaccinated with 2 μg of pcDNA3-CRT/E7 DNA via gene gun delivery. 3 days after the vaccination, the
mice were treated with either 20 mg/kg of DMXAA or buffer via i.p. injection. Mouse serum was collected 5 hours later and stored at -80°C until
assay. Mouse cytokines were analyzed using Bio-Plex Pro Mouse Cytokine 23-plex Assay from Bio-Rad according to manufacturer’s protocol. Each
sample was assayed in duplicate. The data are expressed as means ± SD.
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TNFa contribute to the observed immune suppression
caused by DMXAA administration at the time of the
first DNA vaccination.
Discussion
In the current study, we determined that treatment with
DMXAA generates significant therapeutic effects against
TC-1 tumors but does not enhance the antigen-specific
immune responses in tumor bearing mice. We further
found that combination of DMXAA treatment with
therapeutic HPV DNA vaccination generates potent
antitumor effects and E7-specific CD8+ T cell immune
responses in tumor bearing mice. Furthermore, the
DMXAA-mediated enhancement or suppression of E7-
specific CD8+ T cell immune responses generated by
CRT/E7 DNA vaccination was found to be dependent
on the time of administration of DMXAA and was also
applicable to other antigen-specific vaccines. In addition,
we determined that iNOS plays a role in the immune
suppression caused by DMXAA administration before
DNA vaccination. Our data are consistent with a recent
observation using E7 peptide-based vaccines in an E7-
expressing cervicovaginal tumor model [20].
Figure 8 Characterization of the E7-specific CD8+ T cell immune responses in iNOS and TNF-a knockout mice treated with HPV-16 E7
DNA vaccine in combination with DMXAA. A&B . Schematic diagram of the immunization regimen of the CRT/E7 DNA vaccine and DMXAA
administered at different time points. 5-8 weeks old wild-type or iNOS deficient (middle panel), or TNF-a deficient (bottom panel) C57BL/6 mice
were vaccinated with pcDNA3-CRT/E7 via gene gun delivery at day 0, and boosted once at day 7. The mice were treated with DMXAA (20 mg/
kg) via i.p. injection either at day 0 (A) or day 3 (D) of the first vaccination. Splenocytes were harvested 7 days after last vaccination, and HPV-16
E7aa49-57-specific-CD8+ T cell responses were analyzed by intracellular IFN-g staining using flow cytometry. B&C . Bar graphs depicting the
number of E7-specific IFNg+ CD8+ T cells per 3 × 10
5 splenocytes in WT, iNOS-/-mice (B) or TNF-a-/- mice (D) ± SEM following DNA vaccination
and DMXAA treatment on D0. E&F . Bar graphs depicting the number of E7-specific IFNg+ CD8+ T cells per 3 × 10
5 splenocytes in WT, iNOS-/-
mice (E) or TNF-a-/- mice (F) ± SEM following DNA vaccination and DMXAA treatment on D3.The data shown here are from one representative
experiment of two performed.
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bearing mice with DMXAA alone leads to therapeutic
antitumor effects without generating antigen-specific
immune responses (Figure 1). This may be due to the
fact that as a vascular disrupting agent, DMXAA has
been shown to exert antitumor effects by non antigen-
specific mechanisms such as selectively destroying the
established tumor vasculature and shutting down blood
supply to solid tumors, causing extensive tumor cell
necrosis [10,11]. The release of tumor antigen caused by
DMXAA treatment may not be sufficient to generate
detectable antigen-specific immune responses. Thus,
while DMXAA treatment alone in TC-1 tumor-bearing
mice failed to lead to appreciable E7 antigen-specific
immune responses, the vaccination with CRT/E7 vac-
cine can lead to increased number of E7-specific CD8+
T cell precursors in tumor-bearing mice, which may be
further expanded by treatment with DMXAA, resulting
in a significant enhancement of E7-specific CD8+
immune responses in treated mice (Figure 2).
For clinical translation, it is important to determine
the optimal regimen for treatment with DMXAA. Our
study showed that administration of DMXAA 3 days
after the first CRT/E7 DNA vaccination generates the
best antigen-specific CD8+ T cell immune responses in
vaccinated mice (Figure 3). Our data also indicated that
administration of two doses of DMXAA after the first
CRT/E7 DNA vaccination generates E7-specific CD8+ T
cell immune responses in vaccinated mice (see Addi-
tional File 1; Figure S1). Thus, it will be of importance
to further explore the optimal treatment for administra-
tion of DMXAA in clinical trials.
Our study explored the mechanism of enhancement
induced by DMXAA. We found that DMXAA adminis-
tered after the first DNA vaccination influences the
cytokine profile in the serum of mice with observed
immune enhancement (Figure 7). Mice treated with
DMXAAA after the first DNA vaccination showed upre-
gulation of the cytokines IL-6, G-CSF, KC, MIP-1b and
RANTES. IL-6 can be secreted by T cells and macro-
phages to stimulate immune response to trauma, leading
to inflammation (for review see [21]). G-CSF is a cyto-
kine produced by a number of different tissues to stimu-
late the bone marrow to produce granulocytes and stem
cells. KC, MIP-1b and RANTES are chemokines that act
as chemo-attractants to guide the migration of T cells.
All these molecules are believed to play a role in the
immune enhancement generated by DMXAA adminis-
tration. In additon, our data suggest that treatment with
DMXAA 3 days after the first DNA vaccination can
lead to enhancement of antigen-specific CD4+ T cells
(Figure 5). Thus, it is possible that the enhancement
of E7-specific CD8+ T cell responses by DMXAA
treatment may also be contributed by both cytokines as
well as antigen-specific CD4+ T cells.
Our data also suggested that iNOS plays a role in the
immune suppression caused by DMXAA administration
at the time of the first DNA vaccination (Figure 8). Our
study also showed that the immune suppression
mediated by DMXAA is abolished in iNOS knockout
mice. Because DCs are essential for priming of antigen-
specific CD8+ T cell immune response, it is conceivable
that treatment with DMXAA may lead to the negative
impact on DC function, presumably mediated by iNOS.
It will be of interest to further characterize the role of
iNOS on immunosuppression mediated by DMXAA
treatment.
In summary, we have demonstrated that the combina-
tion of DMXAA treatment with HPV-16 E7 DNA vacci-
nation can enhance or suppress the antitumor effects
and E7-specific CD8+ T cell immune responses in trea-
t e dm i c ed e p e n d i n go nt h et i m eo fa d m i n i s t r a t i o no f
DMXAA. These results may have potential implications
for future clinical translation.
Additional material
Additional File 1: Figure S1. Characterization of DC number and
function. 5-8 week-old C57BL/6 mice (3 mice/group) were injected with
1×1 0
5 TC-1 cells subcutaneously. On day 13 after tumor injection, the
mice were vaccinated with 2 μg of pcDNA3-CRT/E7 via gene gun
delivery and boosted 3 days later. 3 days after the first vaccination, mice
was treated with 20 mg/kg DMXAA intraperitoneally, and another group
was given same volume of vehicle (5% NaHCO3). 24 hours later, the
tumor draining lymph nodes were harvested and single cell preparation
was prepared. The cells were then stained with anti-mouse CD45-FITC,
anti-mouse CD11c-APC, plus one of the following PE-conjugated
antibodies: anti-mouse ICAM-1, CD40, CD80, CD86. The cells were gated
on CD45 and CD11c positive population. (A) Representative flow
cytometry data. (B) Bar graph representing the expression of DC
activation markers. The number in the figure represents mean
fluorescence intensity (MFI). (C) Bar graph representing the percentage of
CD11c+CD45+ DCs. ** indicated p < 0.001.
Additional File 2: Figure S2. Characterization of the E7-specific CD8
+ T cell immune responses in mice treated with HPV16 E7 DNA
vaccine in combination with two doses of DMXAA. (A) Schematic
diagram of the immunization regimen of the CRT/E7 DNA vaccine and
DMXAA. 5-8 weeks old C57BL/6 mice were vaccinated with pcDNA3-
CRT/E7 DNA vaccine via gene gun delivery and treated with either one
dose or two doses of DMXAA as indicated in Figure 6A. One week after
last vaccination, splenocytes from mice were harvested and characterized
for E7-specific CD8
+ T cells using intracellular IFN-g staining followed by
flow cytometry analysis. (B) Representative data of intracellular cytokine
staining followed by flow cytometry analysis showing the number of E7-
specific IFNg+ CD8+ T cells after DMXAA treatment. (C) Bar graph
depicting the number of E7-specific IFNg+ CD8+ T cells per 3’10
5
splenocytes ± SEM following DNA vaccination +/- DMXAA treatment.
The data shown here are from one representative experiment of two
performed.
Additional File 3: Figure S3. Characterization of the apoptotic T cell
death induced by DMXAA. Bar graph depicting the percentage of
annexin V + cells in T cells treated with or without DMXAA. 5-8 weeks
old C57BL/6 mice were treated with DMXAA at 20 mg/kg via i.p.
injection. 48 hours later, splenocytes were harvested and apoptosis of
Peng et al. Journal of Biomedical Science 2011, 18:21
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Page 10 of 11CD4+ and CD8+ T cells were analyzed by annexin V staining. The data
shown here are from one representative experiment of two performed.
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